Fennec Pharmaceuticals Inc. (FRA:RV41)
6.45
-0.15 (-2.27%)
Last updated: Dec 16, 2025, 8:05 AM CET
Fennec Pharmaceuticals Revenue
Fennec Pharmaceuticals had revenue of $12.46M USD in the quarter ending September 30, 2025, with 78.69% growth. This brings the company's revenue in the last twelve months to $38.79M, down -21.39% year-over-year. In the year 2024, Fennec Pharmaceuticals had annual revenue of $47.54M with 123.69% growth.
Revenue (ttm)
$38.79M
Revenue Growth
-21.39%
P/S Ratio
6.75
Revenue / Employee
$1.21M
Employees
32
Market Cap
223.26M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 47.54M | 26.29M | 123.69% |
| Dec 31, 2023 | 21.25M | 19.72M | 1,284.50% |
| Dec 31, 2022 | 1.54M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 170.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Deutsche Post AG | 84.05B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
Fennec Pharmaceuticals News
- 12 days ago - Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors - GlobeNewsWire
- 19 days ago - Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss - Wallstreet:Online
- 19 days ago - Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss - GlobeNewsWire
- 25 days ago - Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Fennec Pharmaceuticals (FENC) Eliminates Debt with Convertible Notes Buyback - GuruFocus
- 4 weeks ago - Fennec Pharmaceuticals Announces Closing of Offering of Common Shares - GlobeNewsWire
- 5 weeks ago - Fennec Pharmaceuticals (FENC) Plans $5.025M Share Offering in Canada - GuruFocus
- 5 weeks ago - Fennec Pharmaceuticals plans share offering in Canada to raise up to $5 million - Seeking Alpha